Many income investors probably have mixed emotions about stocks with ultra-high dividend yields. On one hand, they love the tremendous income these stocks provide.

Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (PFE 0.06%) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in P...

Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.

The 2025 stock market has been highly volatile, to say the least. While many top stocks have risen above the fray during periods of market recovery, others haven't followed that upward trend.

It's been a tough stretch for pharmaceutical giant Pfizer (PFE 1.42%). The company enjoyed a vaccine windfall during the COVID-19 pandemic, but revenue and profits cratered as the pandemic eased an...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting, signaling a successful turnaround is underway. Key drugs like Vyndaqel, Paxlovid, and L...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. However, given the strong EPS headwinds and large EPS uncertainties, I suggest investors focus on other prof...

The final trades of the day with CNBC's Mike Santoli and the “Fast Money” traders.

Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings re...

Pfizer Inc. (NYSE:PFE ) Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ET Company Participants Aamir Malik - Corporate Participant Albert Bourla - Chairman of the Board & CEO Alexandre de...

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growt...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share...

Pfizer hiked its full-year adjusted profit guidance on its cost cuts and strong business performance this year. The company also reported second-quarter results that topped Wall Street's estimates ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) dilut...